Media stories about Fate Therapeutics (NASDAQ:FATE) have trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fate Therapeutics earned a news impact score of 0.18 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.1742770045201 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Fate Therapeutics (FATE) Given Consensus Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- Stock Traders Purchase Large Volume of Call Options on Fate Therapeutics (FATE) (americanbankingnews.com)
- CBAY Walks The Talk, MYND Explodes, NITE Sparkles, NVLN Awaits CHMP Opinion (finanzen.ch)
- Fate Therapeutics Inc’s (NASDAQ:FATE) Shift From Loss To Profit (finance.yahoo.com)
FATE stock traded up $0.11 during midday trading on Friday, hitting $11.54. The company’s stock had a trading volume of 447,364 shares, compared to its average volume of 621,770. The stock has a market capitalization of $603.18, a PE ratio of -11.31 and a beta of 1.74. Fate Therapeutics has a 12 month low of $2.52 and a 12 month high of $14.45. The company has a current ratio of 9.29, a quick ratio of 9.29 and a debt-to-equity ratio of 0.19.
Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings data on Monday, March 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The business had revenue of $1.03 million during the quarter, compared to the consensus estimate of $1.02 million. Fate Therapeutics had a negative net margin of 1,046.08% and a negative return on equity of 71.00%. The firm’s revenue was up .0% on a year-over-year basis. research analysts predict that Fate Therapeutics will post -0.94 earnings per share for the current year.
A number of brokerages have recently commented on FATE. Zacks Investment Research raised Fate Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research report on Friday, January 19th. Wedbush reaffirmed an “outperform” rating and issued a $19.00 price objective on shares of Fate Therapeutics in a research report on Thursday, March 29th. BidaskClub raised Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 23rd. UBS cut Fate Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 6th. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $12.00 price objective on shares of Fate Therapeutics in a research report on Tuesday, March 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Fate Therapeutics presently has an average rating of “Buy” and a consensus price target of $15.00.
ILLEGAL ACTIVITY WARNING: “Fate Therapeutics (NASDAQ:FATE) Given Daily Media Impact Score of 0.18” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://ledgergazette.com/2018/04/15/fate-therapeutics-fate-receives-daily-media-sentiment-score-of-0-18.html.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.